SAM
IOVA icon

Silphium Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Silphium Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-30,526
Closed -$516K – 128
2018
Q1 		$516K Buy
+30,526
New +$462K 0.28% 39

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Silphium Asset Management's IOVA Position: Q2 2018 in Review

Silphium Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2018, closing a stake of 30,526 shares — an estimated $516K sold.

Silphium Asset Management first reported a position in IOVA in Q1 2018 and held it in 1 quarter. The position peaked at $516K in Q1 2018. 126 funds tracked by Wall St. Rank hold IOVA as of Q2 2018.

  • Silphium Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • Silphium Asset Management sold 30,526 Iovance Biotherapeutics shares in Q2 2018, an estimated $516K.
  • Silphium Asset Management first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 1 quarter.
  • Silphium Asset Management's Iovance Biotherapeutics position peaked at $516K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2018.

Based on Silphium Asset Management's 13F filing for Q2 2018, filed 30 Jan 2025.